Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sellas Life Sciences Group Inc SLS

Healthcare Biotechnology
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor... see more

Recent & Breaking News (NDAQ:SLS)

SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting

GlobeNewswire September 22, 2022

SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th

GlobeNewswire September 14, 2022

SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on September 15, 2022

GlobeNewswire September 8, 2022

SELLAS Life Sciences' Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line

GlobeNewswire August 24, 2022

SELLAS Life Sciences' Announces Election of Katherine Bach Kalin to its Board of Directors

GlobeNewswire August 16, 2022

SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 11, 2022

SELLAS Life Sciences' GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines

GlobeNewswire August 9, 2022

SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009

GlobeNewswire July 7, 2022

SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial

GlobeNewswire June 27, 2022

SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo

GlobeNewswire June 8, 2022

SELLAS Life Sciences to Present at the JMP Securities Life Sciences Conference on June 15th

GlobeNewswire June 2, 2022

SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer

GlobeNewswire May 26, 2022

SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 12, 2022

SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S

GlobeNewswire April 26, 2022

SELLAS Life Sciences' Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study

GlobeNewswire April 11, 2022

SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China

GlobeNewswire April 6, 2022

SELLAS Life Sciences Provides Business Update and First Quarter 2022 Highlights

GlobeNewswire April 5, 2022

SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering

GlobeNewswire March 31, 2022

SELLAS Life Sciences Announces Proposed Underwritten Public Offering

GlobeNewswire March 31, 2022

SELLAS Life Sciences Signs Exclusive License Agreement with GenFleet Therapeutics for Next-Generation, Highly Selective CDK9 Inhibitor

GlobeNewswire March 31, 2022